|本期目录/Table of Contents|

[1]张亚同,张宏,刘俊鹏,等.胺碘酮对房颤消融术后直接口服抗凝药的影响[J].国际心血管病杂志,2020,06:366.
　ZHANG Yatong,ZHANG Hong,LIU Junpeng,et al.Effect of amiodarone on direct oral anticoagulant in patients with atrial fibrillation after radiofrequency ablation[J].International Journal of Cardiovascular Disease,2020,06:366.
点击复制

胺碘酮对房颤消融术后直接口服抗凝药的影响(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2020年06期
页码:
366
栏目:
临床研究
出版日期:
2020-12-15

文章信息/Info

Title:
Effect of amiodarone on direct oral anticoagulant in patients with atrial fibrillation after radiofrequency ablation
作者:
张亚同; 张宏; 刘俊鹏; 李少强; 赵紫楠; 胡欣
100730 北京医院药学部国家老年医学中心(张亚同,赵紫楠,胡欣); 100191 北京大学药学院药事管理与临床药学系(张宏,李少强); 100730 北京医院心内科(刘俊鹏)
Author(s):
ZHANG Yatong1;  ZHANG Hong2;  LIU Junpeng3;  LI Shaoqiang2;  ZHAO Zinan1;  HU Xin1
1.Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Beijing 100730; 2.Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191; 3.Department of Cardiology, Be
关键词:
胺碘酮;  利伐沙班;  达比加群;  心房颤动;  射频消融术;  抗凝
Keywords:
Amiodarone;  Rivaroxaban;  Dabigatran;  Atrial fibrillation;  Radiofrequency ablation;  Anticoagulation
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2020.06.012
文献标识码:
A
摘要:
目的:探讨射频消融术后联用胺碘酮对非瓣膜性心房颤动(房颤)患者直接口服抗凝剂(DOAC)抗凝效果的影响。方法:回顾性分析某三甲医院2012年1月至2018年7月非瓣膜性房颤患者的病历资料,筛选出射频消融术后采用利伐沙班或达比加群抗凝的患者,根据是否联用胺碘酮将患者分为无胺碘酮组(n=41)和胺碘酮组(n=188),评估联用胺碘酮是否影响患者转归和临床事件的发生。结果:两组患者年龄、性别、体质量指数(BMI)、伴随疾病、凝血指标均无统计学差异。应用DOAC至少1个月,胺碘酮组凝血
Abstract:
Objective:To explore the effect of amiodarone on the anticoagulation of direct oral anticoagulant(DOAC)in patients with non-valvular atrial fibrillation after radiofrequency ablation.Methods:The medical records of patients with non-valvular atrial fibrill

参考文献/References

[1] Latchamsetty R, Morady F. Catheter ablation of atrial fibrillation[J]. Cardiol Clin, 2014, 32(4):551-561.
[2] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Eur Heart J, 2016, 37(38):2893-2962.
[3] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials[J]. Lancet, 2014, 383(9921):955-962.
[4] Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects[J]. Br J Clin Pharmacol, 2013, 76(3):455-466.
[5] Summary of product characteristics[EB/OL].(2018-01-08)
[2020-05-26]. https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf
[6] Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial[J]. Heart Rhythm, 2014, 11(6):925-932.
[7] Flaker G, Lopes RD, Hylek EM, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial[J]. J Am Coll Cardiol, 2014, 64(15):1541-1550.
[8] Bohnen M, Stevenson WG, Tedrow UB,et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias[J]. Heart Rhythm, 2011, 8(11):1661-1666.
[9] Darkner S, Chen X,Hansen J, et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation:a double-blind,randomized, placebo-controlled study(AMIO-CAT trial)[J]. Eur Heart J, 2014, 35(47):3356-3364.
[10] Page SP, Herring N, Hunter RJ, et al. Periprocedural stroke risk in patients undergoing catheter ablation for atrial fibrillation on uninterrupted warfarin[J]. J Cardiovasc Electrophysiol, 2014, 25(6):585-590.

备注/Memo

备注/Memo:
基金项目:国家重点研发计划(2016YFC0904900)通信作者:张亚同,E-mail:zyt2002888@qq.com
更新日期/Last Update: 2020-12-15